Hesperetin as an adjuvant augments protective anti-tumour immunity responses in B16F10 melanoma by stimulating cytotoxic CD8
T cells
hesperetin
melanoma
tumour immunity
vaccination
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
11
09
2019
revised:
10
01
2020
accepted:
16
01
2020
pubmed:
25
1
2020
medline:
31
3
2020
entrez:
25
1
2020
Statut:
ppublish
Résumé
Hesperetin (HES) is a dihydroflavone with the molecular formula of C16H14O6. It has been reported that Hesperetin has antioxidant and anticancer effects. Recent studies showed that it can also regulate immune responses. To assess its potential function as a vaccine adjuvant, we formulated HES with inactivated B16F10 melanoma cells and determined whether it would enhance the activation of antigen-presenting cells by experiments in vivo and in vitro. We found that HES activated the PI3K-Akt signalling pathway in antigen-presenting cells (APCs), enhanced cytotoxic T lymphocyte (CTL) responses and deactivated tolerogenic T cells. We also observed that inactivated B16F10 cells in combination with HES vaccine inhibited the growth of mice tumours, resulting in improved overall survival compared to the effects of inactivated B16F10 cell vaccine. To verify that CD8
Substances chimiques
Adjuvants, Immunologic
0
Antineoplastic Agents
0
Cancer Vaccines
0
Hesperidin
E750O06Y6O
hesperetin
Q9Q3D557F1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12867Subventions
Organisme : National Natural Science Foundation of China
ID : 81471958
Organisme : Postdoctoral Research Project of Qingdao
ID : 2015139
Organisme : National Oceanic Administration Open Fund 2017
ID : MBSMAT-2017-01
Informations de copyright
© 2020 The Scandinavian Foundation for Immunology.
Références
Russo A. Targeted therapies for solid tumors. A handbook for moving toward new frontiers in cancer treatment. Anticancer Res. 2010;24:303-316.
Incorvaia L, Badalamenti G, Rinaldi G, et al. Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? Ther Adv Med Oncol. 2019;11:1758835919848872.
Kim HY, Upadhyay PJ, Fahmy A, Liu X, Duong JK, Boddy AV. Clinical pharmacokinetic and pharmacodynamic considerations in the (modern) treatment of melanoma. Clin Pharmacokineti. 2019;58(8):1029-1043.
Misu M, Ouji Y, Kawai N, Nishimura F, Nakamura-Uchiyama F, Yoshikawa M. Effects of Wnt-10b on proliferation and differentiation of murine melanoma cells. Biochem Biophys Res Commun. 2015;463:618-623.
Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.
Tarazona R, Duran E, Solana R. Natural killer cell recognition of melanoma: new clues for a more effective immunotherapy. Front Immunol. 2016;6:649.
Larkin J, Minor D, D'Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in checkmate 037: A randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36(4):383-390.
Schvartsman G, Taranto P, Glitza IC, Agarwala SS, Atkins MB, Buzaid AC. Management of metastatic cutaneous melanoma: updates in clinical practice. Ther Adv Med Oncol. 2019;11:1758835919851663.
Ferraro B, Morrow MP, Hutnick NA, Shin TH. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011;53:296-302.
Shrestha AC, Wijesundara DK, Masavuli MG, Mekonnen ZA, Gowans EJ, Grubor-Bauk B. Cytolytic perforin as an adjuvant to enhance the immunogenicity of DNA vaccines. Vaccines. 2019;7:E38.
Simone V, Simone B, Skibinski DAG, O'Hagan DT, Manmohan S. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. J Pharm Sci. 2012;101:17-20.
Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37:3167-3178.
Vordermeier HM, Dean GS, Rosenkrands I, et al. Adjuvants induce distinct immunological phenotypes in a bovine tuberculosis vaccine model. Clin Vaccine Immunol. 2009;16:1443-1448.
Zou Q, Hu Y, Xue J, et al. Use of praziquantel as an adjuvant enhances protection and Tc-17 responses to killed H5N1 virus vaccine in mice. PLoS ONE. 2012;7:e34865.
Martiñón S, Cisneros A, Villicaña S, Hernández-Miramontes R, Mixcoha E, Calderón-Vargas P. Chemical and immunological characteristics of aluminum-based, oil-water emulsion, and bacterial-origin adjuvants. J Immunol Res. 2019;2019:3974127.
Ding F, Peng W. Biological activity of natural flavonoids as impacted by protein flexibility: an example of flavanones. Mol Biosyst. 2015;11(4):1119-1133.
Miler M, Živanović J, Ajdžanović V, et al. Citrus flavanones naringenin and hesperetin improve antioxidant status and membrane lipid compositions in the liver of old-aged Wistar rats. Exp Gerontol. 2016;84:49-60.
Sassi A, Mokdad BI, Mustapha N, Maatouk M, Ghedira K, Chekir-Ghedira L. Immunomodulatory potential of Hesperetin and Chrysin through the cellular and humoral response. Eur J Pharmacol. 2017;812:S0014299917304624.
Ersoz M, Erdemir A, Duranoglu D, et al. Comparative evaluation of hesperetin loaded nanoparticles for anticancer activity against C6 glioma cancer cells. Artif Cells Nanomed Biotechnol. 2019;47:319-329.
Wang S, Wu B, Xue J, Wang M, Chen R, Wang B. Nizatidine, a small molecular compound, enhances killed H5N1 vaccine cell-mediated responses and protects mice from lethal viral challenge. Hum Vaccin Immunother. 2014;10:461-468.
Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20-21.
Liu H, Geng S, Feng C, et al. A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model. Hum Vaccin Immunother. 2013;9:2196-2202.
Li X, Hu X, Wang J, et al. Inhibition of autophagy via activation of PI3K/Akt/mTOR pathway contributes to the protection of hesperidin against myocardial ischemia/reperfusion injury. Int J Mol Med. 2018;42:1917-1924.
Kuznetsova M, Lopatnikova J, Shevchenko J, Silkov A, Maksyutov A, Sennikov S. Cytotoxic activity and memory T cell subset distribution of in vitro-stimulated CD8(+) T cells specific for HER2/neu epitopes. Front Immunol. 2019;10:1017.
Ghosh S, Jawed JJ, Halder K, et al. TNFα mediated ceramide generation triggers cisplatin induced apoptosis in B16F10 melanoma in a PKCδ independent manner. Oncotarget. 2018;9(102):37627-37646.
Damento GM, Pulido JS, Abbott BA, Hodge DO, Dalvin LA. TNF-Alpha inhibition and other immunosuppressants in the development of uveal and cutaneous melanoma. Mayo Clin Proc. 2019;94(7):1287-1295.
Guinn Z, Brown DM, Petro TM. Activation of IRF3 contributes to IFN-γ and ISG54 expression during the immune responses to B16F10 tumor growth. Int Immunopharmacol. 2017;50:121-129.
Lotz M. Interleukin-6: a comprehensive review. Cancer Treat Res. 1995;80:209.
Hoejberg L, Bastholt L, Schmidt H. Interleukin-6 and melanoma. Melanoma Res. 2012;22:327.
Ann Flørenes V, Lu C, Bhattacharya N, et al. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene. 1999;18:1023-1032.
Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234:8509-8521.
Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18:1.
Müllbacher L, Kos L. Alloreactive cytotoxic T-cell function, peptide nonspecific. Scand J Immunol. 1999;49:563-569.